3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
6
Thoracic
3
Gastrointestinal
3
Other solid neoplasm
2
NET
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
5
Melanoma
2
Uterine Cervical Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Pancreatic Neoplasms
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Filgrastim
15
Carboplatin
10
Ifosfamide
9
Doxorubicin
9
Cyclophosphamide
9
Peripheral Blood Stem Cell Transplantation
7
pembrolizumab
6
Radiotherapy
6
Gemcitabine
6
Temozolomide
5
Etoposide
5
Cisplatin
5
Paclitaxel
4
Docetaxel
4
Amifostine
4
aldesleukin
3
aflibercept
3
Trastuzumab
3
Specimen Handling
3
Radiosurgery
3
Psychiatric Rehabilitation
3
Magnetic Resonance Spectroscopy
3
Biopsy
3
tislelizumab
2
sodium thiosulfate
2
selinexor
2
pazopanib
2
palbociclib
2
etoposide phosphate
2
eribulin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
regorafenib
×
Gynecologic
×
Clear all
NCT02307500
2022-09-10
RESOUND
Istituto Clinico Humanitas
Phase 2
Completed
82 enrolled